Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2018

Open Access 01-12-2018 | Research article

Profiling non-tuberculous mycobacteria in an Asian setting: characteristics and clinical outcomes of hospitalized patients in Singapore

Authors: Albert Y. H. Lim, Sanjay H. Chotirmall, Eric T. K. Fok, Akash Verma, Partha P. De, Soon Keng Goh, Ser Hon Puah, Daryl E. L. Goh, John A. Abisheganaden

Published in: BMC Pulmonary Medicine | Issue 1/2018

Login to get access

Abstract

Background

Non-tuberculous mycobacteria (NTM) infection is an increasing problem worldwide. The epidemiology of NTM in most Asian countries is unknown. This study investigated the epidemiology, and clinical profile of inpatients in whom NTM was isolated from various anatomical sites in a Singaporean population attending a major tertiary referral centre.

Methods

Demographic profile, clinical data, and characteristics of patients hospitalized with NTM isolates at a major tertiary hospital over two-year period were prospectively assessed (2011–2012). Data collected included patient demographics, ethnicity, smoking status, co-morbidities, NTM species, intensive care unit (ICU) treatment, and mortality.

Results

A total of 485 patients (62.1% male) with 560 hospital admissions were analysed. The median patient age was 70 years. Thirteen different NTM species were isolated from this cohort. Mycobacterium abscessus (M. abscessus) (38.4%) was most frequently isolated followed by Mycobacterium fortuitum (M. fortuitum) (16.6%), Mycobacterium avium complex (MAC) (16.3%), Mycobacterium kansasii (M. kansasii) (15.4%), and Mycobacterium gordonae (M. gordonae) (6.8%). Most (91%) NTM was isolated from the respiratory tract. The three most common non-pulmonary sites were; blood (2.7%), skin wounds and abscesses (2.1%), and gastric aspirates (1.1%). A third (34.4%) of the study population had prior pulmonary tuberculosis (PTB). There was a significant association between isolated NTM species, and patient age (p = 0.0002). Eleven (2.2%) patients received intensive care unit (ICU) treatment during the study period and all cause mortality within 1 year of the study was 16.9% (n = 82). Of these, 72 (87.8%) patients died of pulmonary causes.

Conclusions

The profile of NTM species in Singapore is unique. M. abscessus is the commonest NTM isolated, with a higher prevalence in males, and in the elderly. High NTM prevalence is associated with high rates of prior PTB in our cohort.
Literature
1.
go back to reference Falkinham JO 3rd. Environmental sources of nontuberculous mycobacteria. Clin Chest Med. 2015;36:35–41.CrossRefPubMed Falkinham JO 3rd. Environmental sources of nontuberculous mycobacteria. Clin Chest Med. 2015;36:35–41.CrossRefPubMed
2.
go back to reference Bodmer T, Miltner E, Bermudez LE. Mycobacteria avium resists exposure to the acidic conditions of the stomach. FEMS Microbiol Lett. 2000;182:45–9.CrossRefPubMed Bodmer T, Miltner E, Bermudez LE. Mycobacteria avium resists exposure to the acidic conditions of the stomach. FEMS Microbiol Lett. 2000;182:45–9.CrossRefPubMed
3.
go back to reference Kirschner RA Jr, Parker BC, Falkinham JO 3rd. Epidemiology of infection by nontuberculous mycobacterium. Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum in acid, brown-water swamps of southeastern United States and their association with environmental variables. Am Rev Respir Dis. 1992;145:271–5.CrossRefPubMed Kirschner RA Jr, Parker BC, Falkinham JO 3rd. Epidemiology of infection by nontuberculous mycobacterium. Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum in acid, brown-water swamps of southeastern United States and their association with environmental variables. Am Rev Respir Dis. 1992;145:271–5.CrossRefPubMed
4.
go back to reference Falkinham JO 3rd. Growth in catheter biofilms and antibiotic resistance of Mycobacterioum avium. J Med Microbiol. 2007;56:250–4.CrossRefPubMed Falkinham JO 3rd. Growth in catheter biofilms and antibiotic resistance of Mycobacterioum avium. J Med Microbiol. 2007;56:250–4.CrossRefPubMed
5.
go back to reference Mirsaeidi M, Machado RF, Garcia JGN, Schraufnagel DE. Nontuberculous mycobacterial disease mortality in the United States, 1999–2010: a population-based comparative study. PLoS One. 2014;9(3):e91879.CrossRefPubMedPubMedCentral Mirsaeidi M, Machado RF, Garcia JGN, Schraufnagel DE. Nontuberculous mycobacterial disease mortality in the United States, 1999–2010: a population-based comparative study. PLoS One. 2014;9(3):e91879.CrossRefPubMedPubMedCentral
6.
go back to reference Blackwood KS, He C, Gunton J, Turenne CY, Wolfe J, Kabani AM. Evaluation of recA sequences for identification of Mycobacterium species. J Clin Microbiol. 2000;38(8):2846–52.PubMedPubMedCentral Blackwood KS, He C, Gunton J, Turenne CY, Wolfe J, Kabani AM. Evaluation of recA sequences for identification of Mycobacterium species. J Clin Microbiol. 2000;38(8):2846–52.PubMedPubMedCentral
7.
go back to reference Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Non-tuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis. 2009;49:e124–9.CrossRefPubMed Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Non-tuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis. 2009;49:e124–9.CrossRefPubMed
9.
go back to reference Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011;52:565–71.CrossRefPubMed Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011;52:565–71.CrossRefPubMed
10.
go back to reference Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med. 2015;36:91–9.CrossRefPubMed Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med. 2015;36:91–9.CrossRefPubMed
11.
go back to reference Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Braddley JW, McFarland B, Austin D, Radcliffe L, Suhler E, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013;72:37–42.CrossRefPubMed Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Braddley JW, McFarland B, Austin D, Radcliffe L, Suhler E, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013;72:37–42.CrossRefPubMed
12.
go back to reference Brode SK, Jamieson FB, Ng R, Campitelli MA, Kwong JC, Paterson JM, Li P, Marchand-Austin A, Bombardier C, Marras TK. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015;70:677–82.CrossRefPubMed Brode SK, Jamieson FB, Ng R, Campitelli MA, Kwong JC, Paterson JM, Li P, Marchand-Austin A, Bombardier C, Marras TK. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015;70:677–82.CrossRefPubMed
13.
go back to reference O’Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis. 1987;135:1007–14.PubMed O’Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis. 1987;135:1007–14.PubMed
14.
go back to reference Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med. 2013;34:87–94.CrossRefPubMed Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med. 2013;34:87–94.CrossRefPubMed
15.
go back to reference Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DB. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185:881–6.CrossRefPubMedPubMedCentral Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DB. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185:881–6.CrossRefPubMedPubMedCentral
16.
go back to reference Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, et al. The geographical diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42:1604–13.CrossRefPubMed Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, et al. The geographical diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42:1604–13.CrossRefPubMed
17.
go back to reference American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161:1376–95.CrossRef American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161:1376–95.CrossRef
18.
go back to reference Teo SK, Lo KL. Nontuberculous mycobacterial disease in Singapore. Singap Med J. 1992;33:464–6. Teo SK, Lo KL. Nontuberculous mycobacterial disease in Singapore. Singap Med J. 1992;33:464–6.
19.
go back to reference Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182(7):970–6.CrossRefPubMedPubMedCentral Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182(7):970–6.CrossRefPubMedPubMedCentral
20.
go back to reference Chu H, Zhao L, Xiao H, Zhang Z, Zhang J, Gui T, Gong S, Xu L, Sun X. Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: a meta-analysis. Arch Med Sci. 2014;10(4):661–8.CrossRefPubMedPubMedCentral Chu H, Zhao L, Xiao H, Zhang Z, Zhang J, Gui T, Gong S, Xu L, Sun X. Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: a meta-analysis. Arch Med Sci. 2014;10(4):661–8.CrossRefPubMedPubMedCentral
21.
go back to reference Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax. 2007;62:661–6.CrossRefPubMedPubMedCentral Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax. 2007;62:661–6.CrossRefPubMedPubMedCentral
22.
go back to reference Tang SS, Lye DC, Jureen R, Sng LH, Hsu LY. Rapidly growing mycobacteria in Singapore, 2006–2011. Clin Microbiol Infect. 2015;21:236–41.CrossRefPubMed Tang SS, Lye DC, Jureen R, Sng LH, Hsu LY. Rapidly growing mycobacteria in Singapore, 2006–2011. Clin Microbiol Infect. 2015;21:236–41.CrossRefPubMed
23.
go back to reference Tsukamura M, Kita N, Shimoide H, et al. Studies on the epidemiology of nontuberculous mycobacteriosis in Japan. Am Rev Respir Dis. 1988;137:1280–4.CrossRefPubMed Tsukamura M, Kita N, Shimoide H, et al. Studies on the epidemiology of nontuberculous mycobacteriosis in Japan. Am Rev Respir Dis. 1988;137:1280–4.CrossRefPubMed
24.
go back to reference Maiz L, Giron R, Olveria C, Vendrell M, Nieto R, Martinez-Garcia MA. Prevalence and factors associated with nontuberculous mycobacteria in non-cystic fibrosis bronchiectasis: a multicentre observational study. BMC Infect Dis. 2016;16:437–44.CrossRefPubMedPubMedCentral Maiz L, Giron R, Olveria C, Vendrell M, Nieto R, Martinez-Garcia MA. Prevalence and factors associated with nontuberculous mycobacteria in non-cystic fibrosis bronchiectasis: a multicentre observational study. BMC Infect Dis. 2016;16:437–44.CrossRefPubMedPubMedCentral
25.
go back to reference Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, Bai GH. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest. 2006;129:341–8.CrossRefPubMed Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, Bai GH. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest. 2006;129:341–8.CrossRefPubMed
26.
go back to reference Dailloux M, Abalain ML, Laurain C, Lebrun L, Loos-Ayav C, LozniewskiA MJ, the French Mycobacteria Study Group. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J. 2006;28:1211–5.CrossRefPubMed Dailloux M, Abalain ML, Laurain C, Lebrun L, Loos-Ayav C, LozniewskiA MJ, the French Mycobacteria Study Group. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J. 2006;28:1211–5.CrossRefPubMed
27.
go back to reference Simons SO, van Ingen J, Hsueh PR, et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis. 2011;7:343–9.CrossRef Simons SO, van Ingen J, Hsueh PR, et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis. 2011;7:343–9.CrossRef
28.
go back to reference Chakaya J, Kirenga B, Getahun H. Long term complications after completion of pulmonary tuberculosis treatment: a quest for a public health approach. J Clin Tuber Other Mycobact Dis. 2016;3:10–2.CrossRef Chakaya J, Kirenga B, Getahun H. Long term complications after completion of pulmonary tuberculosis treatment: a quest for a public health approach. J Clin Tuber Other Mycobact Dis. 2016;3:10–2.CrossRef
29.
30.
go back to reference Bai X, Feldman NE, Chmura K, Ovrutsky AR, Su W-L, Griffin L, et al. Inhibition of nuclear factor- kappa B activation decreases survival of mycobacterium tuberculosis in human macrophages. PLoS One. 2013;8(4):e61925.CrossRefPubMedPubMedCentral Bai X, Feldman NE, Chmura K, Ovrutsky AR, Su W-L, Griffin L, et al. Inhibition of nuclear factor- kappa B activation decreases survival of mycobacterium tuberculosis in human macrophages. PLoS One. 2013;8(4):e61925.CrossRefPubMedPubMedCentral
31.
go back to reference Xia Z, Dickens M, Raingeaud JL, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinase on apoptosis. Science. 1995;270(5240):1326–31.CrossRefPubMed Xia Z, Dickens M, Raingeaud JL, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinase on apoptosis. Science. 1995;270(5240):1326–31.CrossRefPubMed
32.
go back to reference Pearson G, Robinson F, Beers Gibson T, Xu B-E, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22(2):152–83. Pearson G, Robinson F, Beers Gibson T, Xu B-E, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22(2):152–83.
33.
go back to reference Esther CR Jr, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibrosis. 2010;9:117–23.CrossRef Esther CR Jr, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibrosis. 2010;9:117–23.CrossRef
Metadata
Title
Profiling non-tuberculous mycobacteria in an Asian setting: characteristics and clinical outcomes of hospitalized patients in Singapore
Authors
Albert Y. H. Lim
Sanjay H. Chotirmall
Eric T. K. Fok
Akash Verma
Partha P. De
Soon Keng Goh
Ser Hon Puah
Daryl E. L. Goh
John A. Abisheganaden
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2018
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-018-0637-1

Other articles of this Issue 1/2018

BMC Pulmonary Medicine 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine